Quote this publication Share Print

SALBUMOL (salbutamol), beta-2 agonist – labour inhibitor

TRANSPARENCY COMMITTEE OPINION
Opinions on drugs - Posted on Aug 29 2018

Reason for request

Renewal of inclusion

Insufficient clinical benefit to justify its reimbursement in the short-term treatment of uncomplicated preterm labour and in emergency use in specific obstetric scenarios due to potentially severe maternal adverse cardiopulmonary effects

 

  • SALBUMOL has MA for the short-term treatment of uncomplicated premature labour and for emergency use in specific obstetric scenarios.

  • Betamimetic tocolytics are not recommended due to the existence of potentially severe maternal adverse cardiopulmonary effects.

  • SALBUMOL no longer has a role in the therapeutic strategy

 

 


Clinical Benefit

Insufficient

-


All our publications